This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor


Yin Cui, MD, PhD; Sung-Wan Kim, MD, PhD; Bong Ju Lee, MD, PhD; Jung Jin Kim, MD, PhD; Je-Chun Yu, MD; Kyu Young Lee, MD, PhD; Seunghee Won, MD, PhD; Seung-Hwan Lee, MD, PhD; Seung-Hyun Kim, MD, PhD; Shi Hyun Kang, MD, PhD; Euitae Kim, MD, PhD; Yan Hong Piao, MD; Nam-In Kang; and Young-Chul Chung, MD, PhD

Published: April 24, 2019


In the article “Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia: A Randomized, Open-Label, Review Board-Blinded 15-Month Study” by Larry Alphs, MD, PhD, and colleagues published in the May 2015 issue (J Clin Psychiatry 2015;76[5]:554-561), values in Table 1 have been corrected as follows: 59.9% of Black/African American subjects received oral antipsychotics, the PSP total score standard deviation in the paliperidone palmitate group is 12.8, and the PSP total score mean (SD) in the oral antipsychotic group is 55.0 (12.7). On page 558, in the “Adherence” paragraph, the percentage of subjects with a medication possession ratio greater than 80% when clinician-based “prescription” records were used to assess oral medication adherence is 78.6%.

Volume: 80

Quick Links: